

6-299

06-04-1999

FORM PTO-1595

F



101055335

3ET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Attorney Docket No. C94-007-1

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Cohesion Technologies, Inc., a Delaware CorporationAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name

Other: _____

Execution Date: May 24, 1999

2. Name and address of receiving party(ies):

Name: Cohesion Technologies, Inc.
Address: 2500 Faber Place
Palo Alto, CA 94303Name: Pharming BV
Address: Niels Bohrweg 11-13
2333 CA Leiden
The NetherlandsAdditional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s): See below

If this document is being filed together with a new application, the filing date of the application is:

A. Patent Application No.(s)

B. Patent No.(s) 5,667,839Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Richard Aron OsmanAddress: Science & Technology Law Group75 Denise DriveHillsborough, CA 940106. Total number of applications and patents involved: 17. Total fee (37 CFR 3.41): \$40.00☒ Enclosed☐ Authorized to be charged to deposit account, if necessary

8. Deposit account number:

19-0750

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*Rebecca Graff
Name of Person Signing
Signature5/26/99
DateTotal number of pages including cover sheet: 2

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

**Box Assignment,
U.S. Patent and Trademark Office
Office of Public Records, Crystal Gateway 4, Room 335
Washington, DC 20231**

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

06/03/1999 DNGUYEN 00000114 5667839

01 FC:581

40.00 PP

PATENT
REEL: 009987 FRAME: 0615

ASSIGNMENT

This ASSIGNMENT (the "Assignment") is made from Cohesion Technologies, Inc., a Delaware corporation (the "Assignor") to Cohesion Technologies, Inc., a Delaware Corporation, and Pharming BV, a corporation under the laws of the Netherlands (the "Assignees"), jointly, pursuant to their Amended and Restated Research, License and Supply Agreement dated February 20, 1996, as amended by their Amendment to Agreement dated September 16, 1998 and effective January 1, 1998 (the "Agreement").

Assignor desires to assign to Assignees all of Assignor's right, title and interest in and to the invention entitled *Production of Human Recombinant Collagen in the Milk of Transgenic Animals* disclosed in the patent application having serial no. 08/183,648, filed on January 18, 1994, now U.S. Patent No. 5,667,839, issued on September 16, 1997.

In consideration for entering into the Agreement and for other good and valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, Assignor has sold, assigned, and set over and by these presents does hereby sell, assign, and set over unto the said Assignees and said Assignees' legal representatives, successors and assigns, the entire right, title, and interest (a) in and to said invention (b) in and to all rights to apply for foreign patents on said invention; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, continuation or nonprovisional 37CFR 1.53(b) application of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents; and Assignors do hereby authorize and request the Commissioner of Patents and Trademarks to issue said patents to the above-mentioned Assignees agreeably with the terms of this assignment.

Assignor hereby authorizes the above-mentioned Assignees or their legal representative to insert in this instrument the filing date and serial number of said applications, patents or any other information that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Upon said consideration, Assignor does hereby covenant and agree with the said Assignees that Assignor will not execute any writing or do any act whatsoever conflicting with these presents, and that Assignor will at any time upon request, without further or additional consideration, but at the expense of the said Assignees, execute such additional assignments and other writings and do such additional acts as said Assignees may deem necessary or desirable to perfect the Assignees' enjoyment of this grant, and render all necessary assistance in making application for and obtaining original, divisional, renewal, reissued or extended patents of the United States or of any and all foreign countries on said invention, and in enforcing any rights or cause in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the assigns and legal representatives of both parties.

COHESION TECHNOLOGIES, INC.

Date: 24 MAY 1999 By: David Foster
David Foster
Chief Executive Officer